- Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
-
Park MJ, Kim H, Kim MG, Kim K
- KMID: 2543988
- Clin Mol Hepatol.
- 2023 Jul;29(3):693-704.
- doi: 10.3350/cmh.2022.0330
Background/Aims: Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP-1RA) and thiazolidinedione (TZD) can improve nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH). However, comprehensive research comparing the... -
- CITED
-
- Close
- SHARE
-
- Close
- Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Lin TY, Kang EYC, Shao SC, Lai ECC, Garg SJ, Chen KJ, Kang JH, Wu WC, Lai CC, Hwang YS
- KMID: 2542516
- Diabetes Metab J.
- 2023 May;47(3):394-404.
- doi: 10.4093/dmj.2022.0221
Background: To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care. Methods: This retrospective cohort study... -
- CITED
-
- Close
- SHARE
-
- Close
- Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors
-
Chan ATP, Tang SCW
- KMID: 2540197
- Kidney Res Clin Pract.
- 2022 Nov;41(6):682-698.
- doi: 10.23876/j.krcp.21.285
Progress in the treatment of diabetic kidney disease (DKD) has been modest since the early trials on renin-angiotensin-aldosterone system inhibitors (RAASis). Although sodium-glucose co-transporter 2 inhibitors (SGLT2is) have revolutionized the... -
- CITED
-
- Close
- SHARE
-
- Close
- Effect of the Glucagon-Like Peptide-1 Receptor Agonists on Autonomic Function in Subjects with Diabetes: A Systematic Review and Meta-Analysis
-
Greco C, Santi D, Brigante G, Pacchioni C, Simoni M
- KMID: 2536148
- Diabetes Metab J.
- 2022 Nov;46(6):901-911.
- doi: 10.4093/dmj.2021.0314
Background: In addition to the metabolic effects in diabetes, glucagon-like peptide 1 receptor (GLP-1R) agonists lead to a small but substantial increase in heart rate (HR). However, the GLP-1R actions... -
- CITED
-
- Close
- SHARE
-
- Close
- Diabetic kidney disease treatment: new perspectives
-
Tong LL, Adler SG
- KMID: 2535413
- Kidney Res Clin Pract.
- 2022 Sep;41(Suppl 2):S63-S73.
- doi: 10.23876/j.krcp.21.288
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease and end-stage kidney disease worldwide, as the obesity epidemic and the burden of diabetes continue to rise globally.... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacotherapy in obesity: the current state and the near future
-
Cho YJ, Kim KK
- KMID: 2532666
- J Korean Med Assoc.
- 2022 Aug;65(8):514-531.
- doi: 10.5124/jkma.2022.65.8.514
Background: In Korea, the prevalence of obesity, morbid obesity with serious complications, and childhood obesity are rapidly increasing. To control the obesity pandemic, both prevention and treatment are essential strategic... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
-
Kim HS, Yoon T, Jung CH, Park JY, Lee WJ
- KMID: 2531969
- Diabetes Metab J.
- 2022 Jul;46(4):658-662.
- doi: 10.4093/dmj.2021.0232
Sodium-glucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1RA) are novel anti-diabetic drugs whose glucose-lowering effect and cardiovascular and renal benefits were evidenced in clinical trials. We investigated... -
- CITED
-
- Close
- SHARE
-
- Close
- Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
-
Lee J, Hong SW, Kim MJ, Moon SJ, Kwon H, Park SE, Rhee EJ, Lee WY
- KMID: 2527139
- Endocrinol Metab.
- 2022 Feb;37(1):74-83.
- doi: 10.3803/EnM.2021.1293
Background: Dulaglutide, a long-acting glucagon-like peptide-1 receptor agonist (GLP-1RA), has been shown to reduce body weight and liver fat content in patients with type 2 diabetes. Family with sequence similarity... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiorenal Protection in Diabetic Kidney Disease
-
Lee JF, Berzan E, Sridhar VS, Odutayo A, Cherney DZ
- KMID: 2515453
- Endocrinol Metab.
- 2021 Apr;36(2):256-269.
- doi: 10.3803/EnM.2021.987
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were... -
- CITED
-
- Close
- SHARE
-
- Close
- Side Effects Associated with Liraglutide Treatment for Obesity as Well as Diabetes
-
Seo YG
- KMID: 2514137
- J Obes Metab Syndr.
- 2021 Mar;30(1):12-19.
- doi: 10.7570/jomes20059
Liraglutide is a glucagon-like peptide-1 receptor agonist used as a treatment for type 2 diabetes mellitus, which has been expanded for use at a higher dose in weight control. Therefore,... -
- CITED
-
- Close
- SHARE
-
- Close
- Best Achievements in Clinical Medicine in Diabetes and Dyslipidemia in 2020
-
Rhee EJ, Kim MK, Lee WY
- KMID: 2513287
- Endocrinol Metab.
- 2021 Feb;36(1):41-50.
- doi: 10.3803/EnM.2021.106
Over the last two decades, our understanding of diabetes and treatment strategies have evolved tremendously, from scientific, mechanistic, and human perspectives. The categories of anti-diabetic medications expanded from a few... -
- CITED
-
- Close
- SHARE
-
- Close
- A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
-
Sargeant J, Henson J, King JA, Yates T, Khunti K, Davies MJ
- KMID: 2458626
- Endocrinol Metab.
- 2019 Sep;34(3):247-262.
- doi: 10.3803/EnM.2019.34.3.247
Weight loss is an important goal in the management of several chronic conditions, including type 2 diabetes mellitus, and pharmacological therapies that aid weight loss are appealing. Glucagon-like peptide-1 receptor... -
- CITED
-
- Close
- SHARE
-
- Close
- The Effects of Hypoglycemic Agents on Non-alcoholic Fatty Liver Disease: Focused on Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
-
Jung CH, Mok JO
- KMID: 2452623
- J Obes Metab Syndr.
- 2019 Mar;28(1):18-29.
- doi: 10.7570/jomes.2019.28.1.18
The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2)... -
- CITED
-
- Close
- SHARE
-
- Close
- Update on the Impact, Diagnosis and Management of Cardiovascular Autonomic Neuropathy in Diabetes: What Is Defined, What Is New, and What Is Unmet
-
Spallone V
- KMID: 2460969
- Diabetes Metab J.
- 2019 Feb;43(1):3-30.
- doi: 10.4093/dmj.2018.0259
The burden of diabetic cardiovascular autonomic neuropathy (CAN) is expected to increase due to the diabetes epidemic and its early and widespread appearance. CAN has a definite prognostic role for... -
- CITED
-
- Close
- SHARE
-
- Close
- Cardiovascular Outcome Trials of Incretin Therapy (Dipeptidyl Peptidase-4 Inhibitors/Glucagon-Like Peptide-1 Receptor Agonist)
-
Jeong IK
- KMID: 2416256
- J Lipid Atheroscler.
- 2018 Jun;7(1):32-41.
- doi: 10.12997/jla.2018.7.1.32
In 2008, the United States Food and Drug Administration issued guidance which mandated long-term cardiovascular outcome trials (CVOTs) to assess the safety of new antidiabetic drugs for type 2 diabetes.... -
- CITED
-
- Close
- SHARE
-
- Close
- Paradigm Changes in Diabetes Management Guidelines: American Diabetes Association 2018
-
Park JH
- KMID: 2415849
- J Korean Diabetes.
- 2018 Jun;19(2):71-75.
- doi: 10.4093/jkd.2018.19.2.71
The management of type 2 diabetes mellitus should comprise healthy lifestyle modifications along with tailored pharmacologic treatment. Traditionally, the American Diabetes Association (ADA)'s Diabetes Management Guidelines have not prioritized specific... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ
- KMID: 2408656
- J Korean Diabetes.
- 2018 Mar;19(1):35-40.
- doi: 10.4093/jkd.2018.19.1.35
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association 2017... -
- CITED
-
- Close
- SHARE
-
- Close
- Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
-
Kim HJ, Park SO, Ko SH, Rhee SY, Hur KY, Kim NH, Moon MK, Lee BW, Kim JH, Choi KM, on behalf of the Committee of Clinical Practice Guidelines of the Korean Diabetes Association
- KMID: 2398081
- Diabetes Metab J.
- 2017 Dec;41(6):423-429.
- doi: 10.4093/dmj.2017.41.6.423
The glucagon-like peptide-1 receptor agonists (GLP-1RAs) were recommended as a monotherapy or combination therapy with oral hypoglycemic agents or basal insulin in the position statement of the Korean Diabetes Association... -
- CITED
-
- Close
- SHARE
-
- Close
- New anti-diabetic agents
-
Kim DM
- KMID: 2397869
- J Korean Med Assoc.
- 2017 Dec;60(12):992-997.
- doi: 10.5124/jkma.2017.60.12.992
Diabetes mellitus is characterized by hyperglycemia due to insulin deficiency and/or insulin resistance. Cardiovascular disease (CVD) is a major comorbidity of type 2 diabetes mellitus, and is the most common... -
- CITED
-
- Close
- SHARE
-
- Close
- New Potential Targets of Glucagon-Like Peptide 1 Receptor Agonists in Pancreatic β-Cells and Hepatocytes
-
Lee WY
- KMID: 2413278
- Endocrinol Metab.
- 2017 Mar;32(1):1-5.
- doi: 10.3803/EnM.2017.32.1.1
It is well known that both insulin resistance and decreased insulin secretory capacity are important factors in the pathogenesis of type 2 diabetes mellitus (T2DM). In addition to genetic factors,... -
- CITED
-
- Close
- SHARE
-
- Close
